2023-08-08 09:02:34 ET
- Corbus Pharmaceuticals press release ( NASDAQ: CRBP ): Q2 GAAP EPS of -$2.05.
-
As of June 30, 2023, the company has $36.6 million of cash, cash equivalents and investments on hand which is expected to fund operations through the second quarter of 2024, based on the current planned expenditures.
- Operating expenses decreased by $4.1 million to approximately $8.2 million for the three months ended June 30, 2023, compared to $12.3 million in the comparable period in the prior year.
For further details see:
Corbus Pharmaceuticals GAAP EPS of -$2.05